Status:
COMPLETED
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This trial is performed for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen...
Detailed Description
Type I allergy is an immune-disorder which stems from the formation of IgE antibodies against proteins and glycoproteins from plants, insects, animals and fungi, most of which are normally considered ...
Eligibility Criteria
Inclusion
- Positive SPT
- Positive EAST
- Positive specific provocation test
Exclusion
- Serious chronic diseases
- Other perennial allergies
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00841516
Start Date
December 1 2007
End Date
May 1 2013
Last Update
November 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. med. Sabina Rak
Gothenburg, Sweden, 41345